International Cannabinoid-Based Drug Discovery and Development (iCBD3) Congress
The inaugural iCBD3 Congress will explore an array of drug targets, therapies, manufacturing processes, regulatory frameworks, clinical studies and market opportunities for cannabinoid-based pharmaceuticals.
Pharmaceutical and biotech development of cannabinoid-based drugs has become a highly active and fertile ground for the generation of a new class of regulated therapeutics. The combination of advancements in our understanding the underlying biology of the endocannabinoid system with the production of natural and synthetic cannabinoid products is now being shown to have myriad therapeutic value for unmet medical conditions.
This programme creates a collaborative environment for building networking relationships across the full range of cannabinoid pharmaceutical discovery and development.
How you will benefit:
Learn about the molecular biology of the endocannabinoid system and new targets for a wide range of diseases.
Apply successful manufacturing, bioprocessing and analytic strategies for cannabinoid products and pharmaceuticals.
Get the latest updates on regulatory standards, clinical studies and market opportunities for cannabinoid pharmaceuticals.
Discover new methods for synthesizing cannabinoids, analogues and derivatives.
Learn about the pharmacology and chemistries of current drugs targeting the endocannabinoid system.
Build on existing partnerships and create new collaborations across industry and academia.
Visit the event webpage to download the full agenda.